Costa Rica vs Somalia: Share of the population living with HIV receiving antiretroviral therapy
Costa Rica
61.6%
in 2024
Somalia
61.9%
in 2024
Costa Rica rank
105th
Somalia rank
104th
Share of the population living with HIV receiving antiretroviral therapy over time
- Costa Rica
- Somalia
How they compare
Somalia currently reports 61.9% against 61.6% in Costa Rica, a difference of 0.3%.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Somalia ahead.
Costa Rica ranks 105th and Somalia ranks 104th of 149 countries.
Costa Rica has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Costa Rica | Somalia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 18.5% | 1.2% | 17.4% | Costa Rica |
| 2010s | 41.2% | 23.9% | 17.3% | Costa Rica |
| 2020s | 59.2% | 51.4% | 7.8% | Costa Rica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Costa Rica or Somalia?
- Somalia, at 61.9% against 61.6% in Costa Rica as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Costa Rica and Somalia?
- 0.3%, with Somalia ahead.
- How many years of comparable data are there for Costa Rica and Somalia?
- 35 years are reported by both, from 1990 to 2024.
- How do Costa Rica and Somalia rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Costa Rica ranks 105th and Somalia ranks 104th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.